A clinical evaluation of safety and immunogenicity of Purified chick embryo cell vaccine and Purified verocell rabies vaccine administered using one week intradermal regimen (4-4-4-0-0) in animal bite cases.

Department of Community Medicine Kempegowda Institute of Medical Sciences KIMS0 sites80 target enrollmentTBD

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Not specified
Sponsor: Department of Community Medicine Kempegowda Institute of Medical Sciences KIMS
Enrollment: 80
Status: Completed
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

4 years ago

Study Type

Interventional

Investigators

Sponsor

Department of Community Medicine Kempegowda Institute of Medical Sciences KIMS

Eligibility Criteria

Inclusion Criteria

•1\) Animal bite cases with category II \& III reporting within 72 hours of exposure
•2\) Subjects willing to give signed informed consent
•3\) Subjects willing to give blood samples on days 0,14,90

Exclusion Criteria

•1\) Subjects who have received anti rabies vaccine and any type of anti\-sera in the past.
•2\) Subjects with chronic diseases like Diabetes Mellitus, Hypertension and Tuberculosis.
•3\) Subjects who are immunocompromised \& are on immunosuppressive therapy like long acting steroids, anti cancer drugs \& radiation therapy.
•4\) Pregnant and lactating women.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed

Phase 4

Protection and Safety of rabies vaccine when administered intradermally

CTRI/2012/06/002720I70

Unknown

Phase 3

A clinical trial to study immunogenicity and safety of Purified Chick Embryo Cell Culture Rabies Vaccine administered intradermallyHealth Condition 1: Z23- Encounter for immunization

CTRI/2010/091/000509Cadila Healthcare Ltd36

Not yet recruiting

Phase 4

Assessment of the protection offered by single dose of COVID-19 vaccines in individuals previously affected with COVID-19

CTRI/2021/10/037099Indian Council of Medical research ICMR

Not yet recruiting

Phase 3

Phase III study of the Cuban vaccine candidate VCN7-T in patients from 1 to 18 years of age at risk of pneumococcal disease in HavanaPneumococcal diseasesVCN7-TPneumococcal InfectionsStreptococcal InfectionsGram-Positive Bacterial InfectionsBacterial Infections

RPCEC00000432Finlay Vaccine Institute (FVI)

Active, not recruiting

Phase 1

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers when Administered Concomitantly with Routine Pediatric Vaccines in the UK.

EUCTR2017-004520-30-GBSanofi Pasteur700